Latest news
Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLiveHCPLive · Fri, 07 Aug 2026 23:10:36 GMTORR vs OS: The Debate Continues on X - OncodailyOncodaily · Fri, 07 Aug 2026 11:25:58 GMTBishal Gyawali: The Commonest Endpoint Now Is Just Tumor Shrinkage - OncodailyOncodaily · Sun, 02 Aug 2026 18:07:32 GMT